Elevated Lipoprotein(a) Predictor of Recurrent Coronary Heart Disease
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 14, 2023 -- Elevated lipoprotein(a) (Lp[a]) is a predictor of recurrent coronary heart disease (CHD) in older adults, according to a study published online June 12 in Current Medical Research & Opinion.
Leon A. Simons, M.D., from the University of New South Wales Sydney, and Judith Simons, from St. Vincent's Hospital, both in Australia, conducted a longitudinal study involving 607 individuals (mean age, 71 years) with prevalent CHD who were followed for 16 years. Lipids and other CHD risk factors were examined at baseline in 1988 to 1989, and the independent contribution of Lp(a) to a further CHD event was assessed.
The researchers identified 399 incident CHD cases. The median Lp(a) was 130 and 105 mg/L in cases and noncases, respectively. Overall, 26 and 19 percent of CHD cases and noncases, respectively, had Lp(a) 300+ mg/L; 18 and 8 percent of cases and noncases, respectively, had Lp(a) 500+ mg/L. Compared with Lp(a) in quintile 1 (<50 mg/L), Lp(a) in quintile 5 (355+ mg/L) significantly predicted recurrent CHD, with a hazard ratio of 1.53, independent of other risk factors. Lp(a) 500+ mg/L versus lower significantly predicted recurrent CHD (hazard ratio, 1.59). Prediction was also significant for Lp(a) 300+ mg/L versus lower (hazard ratio, 1.37).
"Our new results indicate that new therapeutics in development that aim to reduce elevated Lp(a) might help prevent recurrent disease," Simons said in a statement. "However, the potential clinical benefit of therapy to reduce elevated Lp(a) is yet to be confirmed."
Novartis Pharmaceuticals provided an educational grant in support of the present analysis; one author disclosed ties to manufacturers of lipid-modifying drugs.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Noncontact Facial Infrared Thermography Model Can Predict Coronary Artery Disease
WEDNESDAY, June 5, 2024 -- A noncontact facial infrared thermography (IRT) machine learning model can predict coronary artery disease (CAD), according to a study published online...
Plozasiran Reduces Triglyceride Levels in Mixed Hyperlipidemia
MONDAY, June 3, 2024 -- For individuals with mixed hyperlipidemia, plozasiran reduces triglyceride levels at 24 weeks, according to a study published online May 28 in the New...
Volume of Leisure-Time Physical Activity Not Tied to Coronary Artery Calcium
WEDNESDAY, May 22, 2024 -- Ongoing leisure-time physical activity, even at high volumes, is not associated with coronary artery calcium (CAC) progression, a marker of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.